000304300 001__ 304300
000304300 005__ 20250907022527.0
000304300 0247_ $$2doi$$a10.1158/1078-0432.CCR-24-3860
000304300 0247_ $$2pmid$$apmid:40560659
000304300 0247_ $$2ISSN$$a1078-0432
000304300 0247_ $$2ISSN$$a1557-3265
000304300 0247_ $$2altmetric$$aaltmetric:179097620
000304300 037__ $$aDKFZ-2025-01836
000304300 041__ $$aEnglish
000304300 082__ $$a610
000304300 1001_ $$00000-0001-7088-8146$$aWasserman, Jonathan D$$b0
000304300 245__ $$aUpdated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism-Jaw Tumor Syndrome, and Carney Complex.
000304300 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2025
000304300 3367_ $$2DRIVER$$aarticle
000304300 3367_ $$2DataCite$$aOutput Types/Journal article
000304300 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756967815_27123$$xReview Article
000304300 3367_ $$2BibTeX$$aARTICLE
000304300 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304300 3367_ $$00$$2EndNote$$aJournal Article
000304300 520__ $$aHereditary endocrine neoplasia syndromes comprise multiple entities associated with an increased risk for the development of endocrine and nonendocrine neoplasms and other systemic manifestations. These syndromes typically demonstrate autosomal dominant inheritance, and each syndrome is associated with a unique genetic predisposition to a distinct spectrum of tumor susceptibility. Moreover, genotype-phenotype associations within each syndrome may affect the spectrum, penetrance, and age of onset of associated tumors. As many endocrine tumors are benign and/or indolent, a careful approach to monitoring is necessary, wherein the nature, timing of initiation, and frequency of presymptomatic surveillance balance the goal of detecting tumors at a point in which intervention would limit tumor-associated morbidity against the physical, emotional, and financial burdens of surveillance. In this study, we summarize changes in knowledge and practice recommendations related to children with multiple endocrine neoplasia syndromes (types 1, 2A, 2B, 4, and 5), hyperparathyroidism-jaw tumor syndrome, and Carney complex since an initial summary in 2017. These updates reflect the evolving understanding of these complex genetic disorders and aim to improve patient care and outcomes.
000304300 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000304300 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304300 650_2 $$2MeSH$$aHumans
000304300 650_2 $$2MeSH$$aMultiple Endocrine Neoplasia: diagnosis
000304300 650_2 $$2MeSH$$aMultiple Endocrine Neoplasia: genetics
000304300 650_2 $$2MeSH$$aMultiple Endocrine Neoplasia: epidemiology
000304300 650_2 $$2MeSH$$aCarney Complex: diagnosis
000304300 650_2 $$2MeSH$$aCarney Complex: genetics
000304300 650_2 $$2MeSH$$aCarney Complex: epidemiology
000304300 650_2 $$2MeSH$$aChild
000304300 650_2 $$2MeSH$$aGenetic Predisposition to Disease
000304300 650_2 $$2MeSH$$aJaw Neoplasms: diagnosis
000304300 650_2 $$2MeSH$$aJaw Neoplasms: genetics
000304300 650_2 $$2MeSH$$aHyperparathyroidism: diagnosis
000304300 650_2 $$2MeSH$$aHyperparathyroidism: genetics
000304300 7001_ $$00000-0003-0865-8010$$aSchneider, Kami Wolfe$$b1
000304300 7001_ $$00000-0001-6894-1219$$aAchatz, Maria-Isabel$$b2
000304300 7001_ $$00000-0001-5394-8194$$aNakano, Yoshiko$$b3
000304300 7001_ $$00000-0003-0970-1850$$aZelley, Kristin$$b4
000304300 7001_ $$00000-0003-0039-3652$$aGallinger, Bailey$$b5
000304300 7001_ $$00000-0002-3952-881X$$aBauer, Andrew J$$b6
000304300 7001_ $$00000-0002-1935-5157$$aBecktell, Kerri D$$b7
000304300 7001_ $$00000-0003-0894-9301$$aWassner, Ari J$$b8
000304300 7001_ $$00009-0000-8270-8894$$aRaiti, Laura$$b9
000304300 7001_ $$00000-0003-3202-0447$$aDoria, Andrea S$$b10
000304300 7001_ $$00000-0003-0260-3975$$aStates, Lisa J$$b11
000304300 7001_ $$00000-0002-4058-5520$$aStratakis, Constantine A$$b12
000304300 7001_ $$00000-0002-6721-122X$$aBrodeur, Garrett M$$b13
000304300 7001_ $$00000-0002-4073-5509$$aDiller, Lisa R$$b14
000304300 7001_ $$00000-0002-2852-7387$$aKamihara, Junne$$b15
000304300 7001_ $$00000-0001-5752-9763$$aMalkin, David$$b16
000304300 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b17$$udkfz
000304300 7001_ $$00000-0002-7496-4289$$aTamura, Chieko$$b18
000304300 7001_ $$00000-0003-3283-2197$$aVillani, Anita$$b19
000304300 7001_ $$00000-0003-0986-5476$$aWidjaja, Elysa$$b20
000304300 7001_ $$00000-0001-7653-9529$$aDas, Anirban$$b21
000304300 7001_ $$00000-0001-8333-0758$$aRednam, Surya P$$b22
000304300 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-24-3860$$gVol. 31, no. 17, p. 3628 - 3637$$n17$$p3628 - 3637$$tClinical cancer research$$v31$$x1078-0432$$y2025
000304300 909CO $$ooai:inrepo02.dkfz.de:304300$$pVDB
000304300 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000304300 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000304300 9141_ $$y2025
000304300 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000304300 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2024-12-27
000304300 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000304300 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000304300 980__ $$ajournal
000304300 980__ $$aVDB
000304300 980__ $$aI:(DE-He78)B062-20160331
000304300 980__ $$aI:(DE-He78)HD01-20160331
000304300 980__ $$aUNRESTRICTED